Valued at USD 109.50 Billion in 2025 and heading to USD 190.00 Billion by 2035 at a 5.5% CAGR from 2026 to 2035, growth is powered by interleukin and oral targeted launches, FcRn expansion in neuromuscular disease, and North American leadership.
At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.
Research Landscape
We navigate the world of research with two primary approaches:
Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.
Quantitative Research
In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.
Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.
Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.
We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:
The stage entails acquiring market data or relevant information through various sources and methodologies.
We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.
We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.
We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.
The global autoimmune disease therapeutics market was valued at USD 109.50 Billion in 2025 and is estimated at USD 117.10 Billion in 2026. It is forecast to reach USD 190.00 Billion by 2035, growing at a 5.5% CAGR from 2026 to 2035. North America leads with approximately 64% share, while interleukin inhibitors dominate drug classes with approximately 41% share.
Based on research conducted by NMSC, we found that the leading segments and regions stand out as follows.
Values in USD Billion
By Drug Class: Interleukin inhibitors held the largest share, expanding from USD 43.00 Billion in 2025 to USD 77.00 Billion by 2035; B-cell, FcRn and complement targeted therapies is the fastest growing at 8.5% CAGR from 2026–2035.
By Indication: Inflammatory bowel disease held the largest share, expanding from USD 27.00 Billion in 2025 to USD 52.00 Billion by 2035; Myasthenia gravis and other neuromuscular autoimmune diseases is the fastest growing at 12.0% CAGR from 2026–2035.
By Route of Administration: Subcutaneous injection held the largest share, expanding from USD 58.00 Billion in 2025 to USD 98.00 Billion by 2035; Oral is the fastest growing at 8.0% CAGR from 2026–2035.
Dominant Region: North America, growing from USD 71.00 Billion in 2025 to USD 105.00 Billion by 2035.
Fastest-Growing Region: Asia-Pacific at 11.4% CAGR from 2026–2035, rising from USD 12.50 Billion in 2025 to USD 36.50 Billion by 2035.
Dominant Country: U.S., growing from USD 66.40 Billion in 2025 to USD 98.50 Billion by 2035.
Fastest-Growing Country: India at 18.1% CAGR from 2026–2035, rising from USD 0.55 Billion in 2025 to USD 2.90 Billion by 2035.
Our findings suggest an absolute opportunity of USD 72.90 Billion between 2026 and 2035, an attractive investment case for targeted franchises.
According to NMSC analysis, oral therapies rise from 23% of revenue in 2026 to 28% by 2035 as convenience reshapes first line choices.
The infographic outlines the Ecosystem Analysis of the Autoimmune Disease Therapeutics Market, highlighting key stakeholders such as biopharmaceutical companies, research institutions, healthcare providers, and patient advocacy groups. It emphasizes how research innovation, regulatory support, strategic partnerships, and patient awareness contribute to therapeutic development, improved treatment outcomes, and broader market access
The autoimmune disease therapeutics market covers prescription medicines that modulate abnormal immune activity in rheumatoid arthritis, spondyloarthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus and autoimmune neuromuscular disease. This report estimates net manufacturer revenue from originator biologics, biosimilars, oral targeted therapies, and conventional immunosuppressants used for the autoimmune indications included in the defined market scope. Diagnostics, medical devices, atopic dermatitis, and asthma are excluded.
We observed that the structure of this industry is shifting from broad TNF blockade toward mechanism specific interleukin, FcRn and oral targeted options. U.S. Medicare Part D maximum fair prices for Enbrel and Stelara took effect on January 1, 2026, increasing pricing pressure for eligible prescriptions. Biosimilar competition is also intensifying across established biologic franchises. Technology adoption follows, with prefilled syringes, autoinjectors and oral peptides moving administration from the clinic toward the home.
Our assessment indicates that four structural trends are reshaping how autoimmune therapies are developed, priced and delivered through 2035.
Oral options are narrowing the convenience gap that favored injectables. The FDA approved ICOTYDE on 18 March 2026 as the first oral targeted peptide that blocks the IL-23 receptor in plaque psoriasis, supported by four Phase 3 studies in about 2,500 patients. Alongside JAK and TYK2 inhibitors, such launches lift oral revenue in the autoimmune disease therapeutics market from USD 27.00 Billion in 2026 to USD 54.00 Billion by 2035, shifting first line choices toward tablets.
AbbVie reported that Humira net revenues fell 49% in 2025 to USD 4.54 Billion after direct biosimilar competition, and Johnson & Johnson saw Stelara sales decline by almost half in the fourth quarter of 2025. Amgen booked USD 273 million from its own ustekinumab biosimilar, which shows originators hedging their positions. These dynamics shrink TNF inhibitor revenue in the autoimmune disease therapeutics market to USD 12.50 Billion by 2035 while releasing budget for newer classes.
CAR-T cell therapy, first proven in blood cancers, is being studied in refractory lupus and other antibody driven disorders, with the aim of resetting the B cell compartment instead of suppressing it for life. Johnson & Johnson's CARVYKTI shows that commercial scale manufacturing of such products is feasible. We found that autoimmune programs remain investigational, so cell therapy contributes little to the autoimmune disease therapeutics market before 2030 but could redefine treatment later.
argenx reported VYVGART global product net sales of USD 4.15 Billion in 2025, up 90%, and reached 19,000 patients worldwide, while UCB's RYSTIGGO and ZILBRYSQ also gained share. Prefilled syringe launches moved administration toward the home, and label expansion reached seronegative and ocular myasthenia gravis. Our analysis shows that myasthenia gravis and related neuromuscular segments grow at 12.0% CAGR to USD 25.50 Billion by 2035, the fastest in the autoimmune disease therapeutics market.
| Rising diagnosed prevalence and earlier biologic initiation | driver | +1.1% | North America, Europe | 2026–2035 |
| Launch of oral IL-23 receptor and TYK2 targeted therapies | driver | +1.6% | Global | 2026–2032 |
| FcRn and cell therapy expansion in neuromuscular disease and lupus | driver | +1.0% | North America, Europe, Japan | 2027–2035 |
| Reimbursement expansion and local biosimilars in emerging markets | driver | +0.8% | Asia-Pacific, Latin America | 2027–2035 |
| Biosimilar erosion of TNF and ustekinumab franchises | restraint | −1.5% | North America, Europe | 2026–2030 |
| U.S. Medicare price negotiation and Part D redesign | restraint | −0.9% | United States | 2026–2035 |
| Payer step therapy and access barriers | restraint | −0.5% | Global | 2026–2035 |
Expanding diagnosed prevalence is the primary structural driver. The National Institutes of Health reports that an estimated 23.5 million to 50 million Americans live with autoimmune diseases. These conditions are more common in women, although prevalence varies by disease. Any specific percentage of patients who are women should be supported by a source that explicitly reports that statistic. Better access to autoimmune disease diagnostics and earlier biologic initiation convert this large patient pool into treated volume, which supports a 5.5% CAGR for the autoimmune disease therapeutics market from 2026 to 2035.
New mechanisms are lifting treated share. Skyrizi and Rinvoq together generated USD 25.87 Billion for AbbVie in 2025, an increase of more than USD 8 billion, and AbbVie reports that Skyrizi leads frontline treatment in inflammatory bowel disease. Lilly reported positive Phase 3 data for Taltz combined with Zepbound in psoriatic arthritis, and the ICOTYDE approval adds an oral option. These launches expand the autoimmune disease therapeutics market through higher persistence and earlier biologic use.
Price erosion is the main restraint. The Centers for Medicare & Medicaid Services negotiated prices that took effect on 1 January 2026 and cut the 2023 list price of Enbrel from USD 7,106 to USD 2,355 for a 30-day supply, a 67% reduction, and the Stelara price from USD 13,836 to USD 4,695, a 66% reduction. Amgen tied a 48% fall in fourth quarter Enbrel sales to a 35% lower net selling price. In our model such pressure trims growth in the autoimmune disease therapeutics market by about 2.9 percentage points.
Oral IL-23 receptor and TYK2 agents can reach patients who delay injectables, and they benefit psoriasis and inflammatory bowel disease franchises most. Phase 3 studies comparing icotrokinra with deucravacitinib, and a planned head-to-head study against ustekinumab, give prescribers evidence to move earlier. Developers that secure first line positioning capture a durable share of the autoimmune disease therapeutics market.
Selecting a mechanism with biomarkers can raise response rates and reduce cycling between expensive agents, which benefits developers of interleukin, JAK and FcRn classes as well as payers. Rheumatology, bowel disease and lupus programs are adopting serologic and tissue signatures to stratify patients. Sponsors that pair a therapy with a validated signature gain label differentiation and stronger reimbursement arguments.
Asia-Pacific and Latin America hold the largest untreated populations, and Asia-Pacific is projected to grow at 11.4% CAGR. Biosimilars and reimbursement expansion lower entry prices, while telemedicine extends specialist reach beyond major cities. Regional biosimilar producers and developers with tiered pricing and local manufacturing are the principal beneficiaries of this opening.
| Region | 2025 (USD Billion) | 2035 (USD Billion) | CAGR (%) |
|---|---|---|---|
| North America | $10.0 USD Billion | $40.0 USD Billion | 9.0% |
| Europe | $17.1 USD Billion | $51.1 USD Billion | 27.0% |
| Asia-Pacific | $24.2 USD Billion | $62.2 USD Billion | 25.0% |
| Middle East & Africa | $31.3 USD Billion | $73.3 USD Billion | 23.0% |
| Latin America | $38.4 USD Billion | $84.4 USD Billion | 12.0% |
Our findings suggest that competition is concentrated among a few large developers while specialists win in neuromuscular and rare indications.
Competition rests on efficacy, convenience and access. Developers run head-to-head studies, secure formulary positions through rebates, and defend franchises with patient support programs. We observed that price now matters more, because Medicare negotiation and biosimilars compress net prices, so leaders’ pair broad portfolios with lifecycle indications to protect revenue while they roll out newer mechanisms across the autoimmune disease therapeutics market.
Three archetypes stand out. Diversified immunology leaders such as AbbVie, Johnson & Johnson and Novartis defend scale across several mechanisms. Franchise defenders such as Amgen manage mature products like Enbrel and Otezla while building biosimilar positions. Specialist innovators such as argenx and UCB win through differentiated science in neuromuscular disease, hidradenitis suppurativa and psoriasis, with biosimilar entrants as a fourth force.
Differentiation centers on selectivity, dosing convenience and combination strategies. AbbVie plans a Crohn's combination platform pairing Skyrizi with other mechanisms, Lilly is testing Taltz with Zepbound in psoriatic arthritis, and Johnson & Johnson brings an oral peptide to psoriasis. Sponsors that demonstrate clinically meaningful superiority against an active comparator may strengthen their value proposition during reimbursement and formulary negotiations. However, access and pricing outcomes also depend on payer assessments, comparative costs, and local regulations.
Deal making targets assets that extend franchises into oral dosing, new mechanisms and cell therapy. ICOTYDE emerged from a license and collaboration agreement between Protagonist and Johnson & Johnson, which illustrates the partnership model. Geographic expansion also continues, as UCB announced a new U.S. biologics manufacturing facility in Georgia in March 2026, involving approximately USD 2 billion in direct investment and an expected USD 5 billion in total economic impact. Separately, argenx established a presence in Brazil in 2025 to support its regional expansion.
Our findings suggest that the nine companies below, verified through official filings and press releases, lead identifiable autoimmune therapeutic revenue, and ranking beyond fourth place is qualitative.
During our market evaluation, we noticed that 2026 has already delivered approvals, pricing changes and launch milestones that reshape competitive positions.
| Date | Event |
|---|---|
| March 2026 | The FDA approved ICOTYDE (icotrokinra), the first oral targeted peptide IL-23 receptor antagonist, for moderate to severe plaque psoriasis in adults and adolescents. |
Investment opportunities may be strongest in differentiated mechanisms, oral dosing, and neuromuscular indications, subject to clinical evidence, regulatory outcomes, and commercial uptake. argenx reached its first year of operating profitability in 2025, showing that a focused specialist can scale quickly, while established leaders reinvest cash from Skyrizi and Rinvoq into combination platforms. Investors should favor assets with head-to-head evidence and long exclusivity, because net price pressure rewards clear clinical differentiation in the autoimmune disease therapeutics market.
Biologic manufacturing capacity and device assembly are the critical infrastructure layers. UCB announced a new biologics manufacturing facility in Georgia in March 2026, with approximately USD 2 billion in direct investment and an expected USD 5 billion in total economic impact. The facility supports UCB's broader biologics manufacturing capabilities rather than being described as exclusively dedicated to BIMZELX. Partnerships in biologics contract development help smaller sponsors reach commercial scale, and cold chain and autoinjector capacity decide launch speed across the autoimmune disease therapeutics market.
Access and affordability dominate the social dimension, since biosimilars and negotiated prices widen treatment while compressing margins. The burden also falls mostly on women, who represent nearly 80% of patients according to NIH, which raises expectations for inclusive trial design. On the environmental side, cold chain logistics and single use devices raise supply chain emissions that sponsors must now report and reduce.
This report gives pharmaceutical executives a segment-level view of where USD 72.90 Billion of incremental revenue will arise between 2026 and 2035. Leaders can benchmark portfolio mix across six drug classes and six indications, test lifecycle plans against biosimilar erosion, and prioritize launches in the fastest growing neuromuscular and oral segments of the autoimmune disease therapeutics market.
Investors receive reconciled forecasts that tie every segment and region to the global total, together with a transparent restraint model that quantifies price pressure. The matrix of drivers and restraints supports scenario analysis, while the regional table highlights where growth outpaces the 5.5% global CAGR. These tools help investors compare franchises and judge exposure to negotiation, biosimilar and access risks.
Device makers, diagnostics firms and software vendors can align products with the shift toward home administration and precision treatment. Digital therapeutics and adherence tools complement autoinjectors and oral regimens, while biomarker assays support mechanism selection. Product teams can use the route of administration and indication analysis to size addressable demand in the autoimmune disease therapeutics market.
Our findings suggest that the sector expands from USD 117.10 Billion in 2026 to USD 190.00 Billion by 2035, a steady 5.5% path rather than a spike. Growth rests on new mechanisms and neuromuscular expansion, tempered by biosimilar and negotiation pressure. We found that the autoimmune disease therapeutics market stays resilient because treated prevalence keeps rising while mix shifts toward higher value classes.
NMSC's analysis indicates that developers should defend mature franchises through lifecycle indications and pricing discipline, while directing investment toward oral targeted agents, FcRn mechanisms and combination regimens. Companies with biosimilar capability should target emerging markets where reimbursement is widening. Partnerships with local manufacturers and specialist networks will matter more than headline list prices over the next decade.
Investment attractiveness is moderate to high. Absolute growth of USD 72.90 Billion rewards exposure to the fastest segments, yet price erosion rewards selectivity. Assets with clear differentiation, long exclusivity and head-to-head data offer the best risk adjusted returns, whereas mature TNF and ustekinumab exposure carries structural decline and should be weighted cautiously in portfolios.
We observed three shifts: injectables to orals, broad suppression to targeted mechanisms, and clinic to home administration. Key risks include deeper Medicare negotiation, faster biosimilar uptake, safety signals in new classes and macroeconomic volatility in emerging markets. Sponsors should model downside cases for each risk before committing capital to launches in the autoimmune disease therapeutics market.
Our assessment indicates that growth pathways run through oral first line therapy in psoriasis and bowel disease, FcRn expansion in neuromuscular disease, and cell therapy for refractory lupus after 2030. Asia-Pacific access expansion adds volume, while biomarker-guided selection raises response and persistence. Combining these pathways lets leaders outgrow the 5.5% global rate even as older franchises erode.
AbbVie Inc., Full-Year and Fourth-Quarter 2025 Financial Results
news.abbvie.comAbbVie Inc., Form 10-K for fiscal year 2025 (U.S. SEC)
sec.govJohnson & Johnson, Annual Report to Shareholders for 2025 (U.S. SEC)
sec.govJohnson & Johnson, FDA approval of ICOTYDE (icotrokinra), 18 March 2026
jnj.comNovartis AG, Form 20-F for fiscal year 2025 (U.S. SEC)
sec.govNovartis AG, Q4 2025 Interim Financial Report
novartis.comAmgen Inc., Fourth Quarter and Full Year 2025 Financial Results
amgen.comUCB S.A., Half-Year Report 2025
ucb.comEli Lilly and Company, Fourth-Quarter 2025 Financial Results
investor.lilly.com/node/53786/pdfTakeda Pharmaceutical Company Limited, FY2025 Results
takeda.comargenx SE, Full Year 2025 Financial Results (Form 6-K, U.S. SEC)
sec.govCenters for Medicare & Medicaid Services, Medicare Drug Price Negotiation Program: Negotiated Prices for 2026
cms.govNational Institutes of Health, Office of Research on Women’s Health, Updates on Autoimmune Disease Research (December 2025)
orwh.od.nih.govNational Institutes of Health, Office of Research on Women’s Health, Autoimmune Disease Overview
orwh.od.nih.gov
Mayurima Roy is Research Analyst at Next Move Strategy Consulting, where she has spent 4 years working across the firm's full industry coverage rather than a single fixed vertical. Her work centers on structured research, ongoing trend tracking, competitive assessment, and insight-led content development, translating complex market data into clear, decision-ready narratives that support informed client decision-making across diverse global industries, market sectors, and world regions every day.
Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.
Founder, CEO and Board Diector
I have been using Next MSC reports for product positioning in a new geography for a long time. They have by far the best reports I have found and the price is reasonable too!
Strategy Consultant
I have bought the intralogistics market reports from NMSC two times so far. Joseph and his team are always very helpful and flexible in responding to any customization requirements on the report. Their expertise in market reports really helps us steer the day-to-day business. I will definitely recommend and come back myself whenever there is a need.
Partner at Singulier [Ex-BCG]
I recently engaged NEXTMSC.com for a commercial due diligence project within the intralogistics sector, and I am pleased to provide a reference based on my experience. In utilizing NEXTMSC.com's services, I found their report to offer valuable insights into market dynamics and key industry players. The initial report provided a solid foundation for our analysis. However, as we were investigating a smaller target in the market, and I had specific customization requests requiring additional research. These requests included detailed information on product portfolios of various players and sub-market sizes, both inclusive and exclusive of certain product categories. NEXTMSC.com demonstrated commendable responsiveness and agility in accommodating these customization requests. Within a timeframe of 1-2 weeks, they delivered a revised report that met our specific needs. Furthermore, they were receptive to my follow-up inquiries, ensuring clarity and understanding of the data provided. The final deliverable significantly contributed to our due diligence efforts. One of NEXTMSC.com's notable strengths lies in their qualitative research capabilities. However, for future engagements, I would recommend the inclusion of a quantified market model in Excel format. Such a model would offer the ability to conduct in-depth analyses and explore various market segments, including country-specific data and subcomponent breakdowns. Based on my positive experience, I would not hesitate to work with NEXTMSC.com again. Their responsiveness, willingness to accommodate customization requests, and commitment to delivering actionable insights make them a reliable partner for commercial research projects.
Founder & CEO
The EV Charging market research report provided by the NextMSC was exceptionally detailed and insightful. It offered a comprehensive analysis that proved to be a game-changer for our strategic planning. Truly a testament to the NextMSC’s expertise and thoroughness in EV market landscape & analysis.
Chief Manager
Next Move Strategy Consulting is an amazing team of consultants. We required a market study report for our investors on top priority and the team went above and beyond our expectations to deliver the same with ample supporting data within a short time span enabling us to secure the investments and keep our project timeline maintained. Their professionalism, attention to detail, and timely delivery of actionable recommendations have left a lasting impression on our organization.
Alzheimer’s Disease Therapeutics Market
Parkinson's Disease Therapeutics Market Global Industry Analysis and Forecast (2026–2035)
Autoimmune Disease Diagnostics Market
Cancer Therapeutics Market
Parkinson’s Disease Diagnostics Market Global Industry Analysis and Forecast (2026–2035)
Infectious Disease Diagnostics Market
We will customize the research for you if the listed report does not fully match your requirements.
Get 30% Free Customization
U.S. Autoimmune Disease Therapeutics Market
Canada Autoimmune Disease Therapeutics Market
UK Autoimmune Disease Therapeutics Market
Germany Autoimmune Disease Therapeutics Market
France Autoimmune Disease Therapeutics Market
China Autoimmune Disease Therapeutics Market
India Autoimmune Disease Therapeutics Market
Japan Autoimmune Disease Therapeutics Market
South Korea Autoimmune Disease Therapeutics Market
Australia Autoimmune Disease Therapeutics Market
Saudi Arabia Autoimmune Disease Therapeutics Market
UAE Autoimmune Disease Therapeutics Market
South Africa Autoimmune Disease Therapeutics Market
Brazil Autoimmune Disease Therapeutics Market
Argentina Autoimmune Disease Therapeutics Market
